Why We’re In a ‘Golden Age’ of Life Sciences ...

Markets may be pricing in more tightening by the Federal Reserve than is warranted due to a divergence playing out in the economy, according to Goldman Sachs Vice Chairman and former Dallas Fed President Rob Kaplan. In the Goldman Sachs Exchanges podcast, Kaplan notes that while ...  Show more

Rich Friedman, chairman of Goldman Sachs Asset Management, says there are still plenty of investment opportunities in private equity, even as private markets have grown far larger than he would have imagined a few decades ago. In this conversation with Alison Mass, chairman of In ...  Show more

The founders of German biotechnology company BioNTech were researching how to fight cancers using messenger RNA, "the unloved cousin of DNA", when covid-19 first appeared and they realised mRNA could be used to make a vaccine for the disease. Financial Times journalist Joe Miller ...  Show more

In this episode, David Lebovitz, Global Strategist, Multi-Asset Solutions, is joined by Stephen Squinto, Chief Investment Officer, J.P. Morgan Life Sciences Private Capital, to discuss the alternative investment landscape, the private biotech market and areas of opportunity in 20 ...  Show more

For all the exciting developments in the synthetic biology industry, there are also concerns. People can edit genes in their garages these days, so who’s regulating this space?Plus - we’ll hear about the exciting new business models with biology at their core, including one of th ...  Show more

In this week’s series focusing on business and science, we start things off by looking at the world of synthetic biology.The industry is estimated to be worth around $30bn in the next few years, but how is that money actually made?We speak to businesses across the world to find o ...  Show more